|
|
 |
|
Viewing report
|
|
|
|
Cardiovascular Drugs - Global Strategic Business Report
Global Industry Analysts, Inc., April 2010, Pages: 1,058
This report analyzes the worldwide markets for Cardiovascular Drugs in US$ Million. Cardiovascular diseases can be prevented or treated using different classes of drugs. Broadly, the major classes of cardiovascular drugs include: ACE Inhibitors, Angiotensin II Receptor Blockers, Antiarrhythmics, Antithrombotics, Beta Blockers,. Calcium Channel Blockers, Antihyperlipidemics, and Others. The report provides separate comprehensive analytics for US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for each region for the period 2007 through 2015. Also, a six-year historic analysis is provided for these markets. The report profiles 115 companies including many key and niche players such as Abbott Laboratories Inc., AstraZeneca PLC, Bayer AG, Biovail Corp., Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Daiichi Sankyo Company, Ltd., Forest Laboratories, Inc., GlaxoSmithKline PLC, Merck & Co., Inc., Novartis AG, Pfizer, Inc., Sanofi-aventis, Solvay Pharmaceuticals SA, Takeda Pharmaceutical Company Limited, and The Medicines Company. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.
Please note: Reports are sold as single-site single-user licenses. The delivery time for hard copies is between 3-5 business days, as each hard copy is custom printed for the organization ordering it. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks.
For information on site licence pricing please click on Enquire before buying
Customers who bought this item also bought
Anti-Hypertensive Drugs - Global Strategic Business Report
Guide to U.S. Specialty Pharmaceutical Market: Companies, Products and Market Data
Cardiovascular Drug Delivery - Technologies, Markets and Companies
Glaucoma Pharmaceuticals - Global Strategic Business Report
Endpoints - Clinical Trials in Cardiovascular Disorders - Optimal Use of Surrogate Endpoints and Clinical Biomarkers are Key Determinants of Success
The Cardiovascular Market Outlook to 2016
Opthalmic Pharmaceutical Drugs - Global Strategic Business Report
Huntingtons Disease Therapeutics - Global Strategic Business Report
The Global Market for Fixed-Dose Combination Drugs for Leading Diseases
Thought Leader Insight & Analysis Report: Pain/Analgesics Q3 2010
|
|
|
|
